SCF ENCYCLOPEDIA ENTRY

ALZHEIMER’S DISEASE

SCF Registry Code: SCF-RDOS-NEURO-0001-AD

Disease Classification: Neurodegenerative Dementia

Domain: Neurodegeneration • Neuroimmunology • Neuroenergetics • Connectomics • Neurovascular Medicine • Precision Neurology

Parent Registry: SCF-RDOS Neuroscience-Related Disorders and Diseases Indication Registry

I. Definition

ALZHEIMER’S DISEASE (AD) is a progressive neurodegenerative disorder characterized by gradual deterioration of memory, cognition, executive function, language, behavior, and functional independence. It is the most common cause of dementia worldwide and is associated with progressive synaptic dysfunction, neuronal loss, cerebral metabolic failure, neuroimmune dysregulation, and widespread neural network disruption.

Within the Synergistic Compatibility Framework (SCF), ALZHEIMER’S DISEASE is classified as a Neurodegenerative Multi-Omic Convergence Syndrome involving coordinated failures across proteostatic, bioenergetic, neuroimmune, connectomic, and regenerative systems.

II. Epidemiology

III. Etiopathogenic Core

ALZHEIMER’S DISEASE emerges through interaction of genetic susceptibility, age-related biological drift, environmental exposures, vascular dysfunction, metabolic impairment, and neuroimmune dysregulation.

Genetic Drivers

Familial Forms

Primary genes:

• APP
• PSEN1
• PSEN2

Consequences:

• Increased amyloidogenic processing
• Elevated Aβ42 generation
• Accelerated plaque formation

Sporadic Forms

Risk-associated genes:

• APOE ε4
• TREM2
• CLU
• BIN1
• PICALM
• ABCA7

Consequences:

• Impaired amyloid clearance
• Microglial dysfunction
• Synaptic vulnerability

Environmental & Lifestyle Contributors

• Aging
• TYPE 2 DIABETES MELLITUS
• Metabolic syndrome
• Hypertension
• Sleep disorders
• Traumatic brain injury
• Chronic inflammation
• Sedentary lifestyle
• Air pollution exposure
• Vascular disease

IV. SCF Fault Architecture

Applying the SCF Pathophysiology Protocol, ALZHEIMER’S DISEASE demonstrates progressive multi-layer system failure.

V. Molecular Multi-Omics Pathogenesis Map

Genomics

Primary abnormalities:

• APP dysregulation
• APOE-mediated clearance impairment
• PSEN pathway dysfunction

Outcome:

• Amyloid accumulation
• Disease susceptibility

Transcriptomics

Abnormal expression of:

• Neuroinflammatory genes
• Synaptic maintenance genes
• Neuroplasticity regulators

Outcome:

• Reduced adaptive neuronal function

Epigenomics

Features:

• DNA methylation alterations
• Histone modification changes
• Accelerated epigenetic aging

Outcome:

• Persistent pathological signaling

Proteomics

Key abnormalities:

• Amyloid-beta plaques
• Hyperphosphorylated tau
• Synaptic protein depletion

Outcome:

• Synaptic dysfunction
• Neurodegeneration

Metabolomics

Abnormalities:

• Cerebral glucose hypometabolism
• Mitochondrial dysfunction
• ATP deficiency
• Lipid metabolism disturbances

Outcome:

• Energy collapse
• Reduced neuronal survival

Interactomics

Affected pathways:

• PI3K/Akt
• mTOR
• NF-κB
• MAPK
• GSK3β

Outcome:

• Inflammation
• Tau pathology
• Cell death signaling

Connectomics

Affected regions:

• Hippocampus
• Entorhinal cortex
• Default Mode Network
• Fronto-parietal networks

Outcome:

• Memory impairment
• Executive dysfunction

Biomechanicalomics

Features:

• ECM remodeling
• Perineuronal net degradation
• Mechanical signal disruption

Outcome:

• Reduced regenerative capacity

VI. Pathogenesis Flow (SCF Logic)

VII. Clinical Manifestations

Early Stage

• Episodic memory impairment
• Word-finding difficulty
• Mild executive dysfunction
• Reduced concentration

Intermediate Stage

• Progressive memory loss
• Disorientation
• Behavioral changes
• Judgment impairment
• Functional decline

Advanced Stage

• Severe dementia
• Loss of language
• Loss of independence
• Dysphagia
• Immobility

VIII. Diagnostic Framework

Clinical Evaluation

• Neurological examination
• Neuropsychological assessment
• Functional evaluation

Cerebrospinal Fluid Biomarkers

Typical findings:

• Reduced Aβ42
• Elevated total tau
• Elevated phospho-tau

Blood Biomarkers

Emerging markers:

• pTau217
• pTau181
• Neurofilament Light Chain

Neuroimaging

MRI

Findings:

• Hippocampal atrophy
• Cortical thinning
• Temporal lobe degeneration

PET

Findings:

• Amyloid deposition
• Tau deposition
• Cerebral hypometabolism

IX. SCF Disease Tier Classification

X. Pathogens → Symptomatology → SCF Fault Tier Mapping

XI. SCF Therapeutic Mechanisms

SCF-PCR Preventative

Objectives:

• Preserve mitochondrial function
• Maintain neurovascular integrity
• Reduce inflammatory priming
• Support proteostatic balance

SCF-PCR Curative

Objectives:

• Reduce amyloid burden
• Modulate tau pathology
• Suppress neuroinflammation
• Restore neuronal metabolism

SCF-PCR Restorative

Objectives:

• Rebuild synaptic networks
• Enhance neuroplasticity
• Restore connectomic coherence
• Promote regenerative signaling

XII. PROJECT RHENOVA — Integration Pathways

Neuroimmune Axis

Primary targets:

• TREM2
• NLRP3 inflammasome
• NF-κB

Neuroenergetic Axis

Primary targets:

• AMPK
• SIRT1
• Mitochondrial biogenesis pathways

Neurovascular Axis

Primary targets:

• Blood-brain barrier preservation
• Cerebral perfusion maintenance

Connectomic Axis

Primary targets:

• Synaptic integrity
• Network synchronization

Regenerative Axis

Primary targets:

• BDNF signaling
• Neuroplasticity
• Neural repair pathways

XIII. SCF Therapeutic Reconstruction Blueprint

XIV. SCF Strategic Research Prioritization

XV. Next Strategic Research Pathways

Pathway 1

Multi-omic ALZHEIMER’S DISEASE subtype classification.

Pathway 2

TREM2- and microglia-directed precision therapeutics.

Pathway 3

Tau propagation interruption platforms.

Pathway 4

Mitochondrial rescue and bioenergetic restoration programs.

Pathway 5

Connectomics-guided neural network reconstruction.

Pathway 6

Regenerative neuroplasticity enhancement strategies.

Pathway 7

SCF-engineered multi-target therapeutic architectures utilizing Targeted Drug Action, Pharmacokinetic Optimization, Metabolic Efficiency, Resistance Prevention, and Safety Profile integration.

SCF ENCYCLOPEDIA SUMMARY

ALZHEIMER’S DISEASE is a progressive neurodegenerative convergence disorder characterized by proteostatic failure, neuroimmune dysregulation, mitochondrial dysfunction, connectomic fragmentation, and regenerative decline. Within the SCF framework, the disease represents a multi-system failure state requiring integrated Preventative–Curative–Restorative therapeutic reconstruction across genetic, proteomic, metabolic, immune, vascular, and neural network domains.